Amicus Therapeutics, Inc. (FOLD) stock saw a decline, ending the day at $9.61 which represents a decrease of $-0.04 or -0.41% from the prior close of $9.65. The stock opened at $9.6 and touched a low ...

Amicus Therapeutics, Inc. (FOLD) stock saw a decline, ending the day at $9.02 which represents a decrease of $-0.44 or -4.65% from the prior close of $9.46. The stock opened at $9.34 and touched a low ...

Equities researchers at Leerink Partnrs boosted their Q4 2024 earnings per share estimates for Amicus Therapeutics in a ...

Amicus Therapeutics, Inc. (NASDAQ ... If you are looking for an AI stock that is more promising than FOLD but that trades at less than 5 times its earnings, check out our report about the cheapest ...

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance.

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on FOLD stock, giving a Buy rating on January 13.Stay Ahead of ...

Amicus Therapeutics, Inc. (NASDAQ ... Investors are bullish on the stock due to the increasing demand for its medicines in growing markets, accelerating profitability, strong intellectual property ...

Amicus Therapeutics Inc stock price live, this page displays NASDAQ FOLD stock exchange data. View the FOLD premarket stock price ahead of the market session or assess the after hours quote.

According to InvestingPro data, analyst targets for the stock range from $12 to $21, suggesting potential upside. The financial institution's analysis followed Amicus Therapeutics' fiscal year ...

An insider trading activity happens when corporate insiders trade in stock in their own companies. Insider trading information is an indicator that can be used to gain valuable insights and as a ...

In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ...

On Tuesday, Goldman Sachs (NYSE:GS) reiterated its Neutral rating for Amicus Therapeutics (NASDAQ:FOLD) shares, maintaining a $14.00 price target. According to InvestingPro data, analyst targets for ...